Artiva Ends AlloNK Autoimmune Cell Therapy After Two Trial Deaths, One Unexplained, and Cuts 94% of Staff
Artiva Biotherapeutics halted its AlloNK cell therapy trial for autoimmune diseases after two participant deaths, one linked to chemotherapy. The company will cut 94% of its staff and explore strategic options, including a sale or dissolution. AlloNK was tested with rituximab in rheumatoid arthritis and other autoimmune diseases. Artiva reported $319.1 million in cash as of September 30.
How this was made

The 30-second read
Why it matters
The termination removes a potential new therapy from the pipeline and signals heightened safety concerns for autoimmune cell‑therapy approaches.
Market read
The news highlights risk in the autoimmune cell‑therapy space and may affect investor sentiment toward similar biotech programs.
What to watch
Low staff count and remaining assets could make Artiva an attractive acquisition target for larger biotech firms.
Background
Artiva Biotherapeutics announced it is ending development of its AlloNK autoimmune cell‑therapy after two trial deaths and will cut about 94% of its workforce, while exploring merger, sale, or liquidation options.
Market effects
Biotech sector may face heightened scrutiny on autoimmune cell‑therapy programs.
US biotech investors could reassess exposure to early‑stage cell‑therapy companies.
The setback may dampen global sentiment toward autoimmune cell‑therapy development.
Counterpoint
Some investors may view the collapse as a buying opportunity in other autoimmune programs that remain viable.
Key entities
- companyArtiva Biotherapeutics
Private biotech developing AlloNK cell‑therapy for autoimmune diseases.
- regulatorFDA
U.S. regulator that paused enrollment after the deaths.



